This paper is in the following e-collection/theme issue:

Pilot studies (ehealth) (258)

Published on in Vol 6, No 7 (2022): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34248, first published .
The Burden of Cold Agglutinin Disease on Patients’ Daily Life: Web-Based Cross-sectional Survey of 50 American Patients

The Burden of Cold Agglutinin Disease on Patients’ Daily Life: Web-Based Cross-sectional Survey of 50 American Patients

The Burden of Cold Agglutinin Disease on Patients’ Daily Life: Web-Based Cross-sectional Survey of 50 American Patients

Authors of this article:

Florence Joly1 Author Orcid Image ;   Lisa Anne Schmitt2 Author Orcid Image ;   Patricia Ann McGee Watson3 Author Orcid Image ;   Emilie Pain4 Author Orcid Image ;   Damien Testa5 Author Orcid Image
Article Authors Cited by (9) Tweetations (2) Metrics

Journals

  1. Röth A, Broome C, Barcellini W, Jilma B, Hill Q, Cella D, Tvedt T, Yamaguchi M, Lee M, Shafer F, Wardęcki M, Jiang X, Patel P, Joly F, Weitz I. Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA study. European Journal of Haematology 2023;110(3):280 View
  2. Röth A, Broome C, Barcellini W, Tvedt T, Miyakawa Y, D’Sa S, Cella D, Bozzi S, Jayawardene D, Yoo R, Shafer F, Wardęcki M, Weitz I. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Advances 2023;7(19):5890 View
  3. Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost‐effectiveness of sutimlimab in cold agglutinin disease. American Journal of Hematology 2024;99(8):1475 View
  4. Jalink M, Jacobs C, Khwaja J, Evers D, Bruggeman C, Fattizzo B, Michel M, Crickx E, Hill Q, Jaeger U, Kater A, Mäkelburg A, Breedijk A, te Boekhorst P, Hoeks M, de Haas M, D’Sa S, Vos J. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Advances 2024;8(11):2622 View
  5. Berentsen S. Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy. Current Oncology Reports 2024;26(9):1085 View
  6. Berentsen S, Vos J, Malecka A, Tjønnfjord G, D’Sa S. The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms. Expert Review of Hematology 2024;17(8):479 View
  7. Röth A, Broome C, Barcellini W, Jilma B, Hill Q, Cella D, Anderson Tvedt T, Yamaguchi M, Murakhovskaya I, Lee M, Shafer F, Wardęcki M, Jayawardene D, Yoo R, Msihid J, Weitz I. Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension. eClinicalMedicine 2024;74:102732 View
  8. Cella D, Hill Q, Karaouni A, Joly F, Sourdille T, Shafer F, Wardęcki M, Kosinski M, Röth A. FACIT-Fatigue scale in patients with cold agglutinin disease: psychometric validation and estimation of clinically meaningful change. Frontiers in Hematology 2025;4 View

Books/Policy Documents

  1. Bashir S, Chew A. Rook's Textbook of Dermatology. View